SEARCH

Current Edition

A high-profile gene therapy biotech takes aim at Huntington’s

Huntington’s was the first illness ever traced back to changes in a specific chromosome. And yet, almost 40 years since that discovery, no drug has been proven to alter a course of the disease. This year alone saw experimental genetic medicines from Wave Life Sciences and partners Roche and Ionis Pharmaceuticals fail in closely watched clinical trials. Another program, from Voyager Therapeutics, was shuttered as well.

The hunt for an effective medicine hasn’t stopped, though. An analysis from the investment bank Piper Sandler found nine gene therapies for Huntington’s in development as of September. While most were preclinical, one from the Dutch biotech UniQure has advanced into the early stages of human testing, with initial data expected late next year.

Huntington’s is now on Passage’s radar, too, adding to a list of research targets that spans from dementia and ALS to lesser-known neurodegenerative illnesses like Krabbe disease and GM1 gangliosidosis. Factoring in the Huntington’s and Canavan programs, Passage has three therapies in human trials and another six in preclinical testing.

The Gene Therapy Program has been essential to that pipeline growth, given it’s responsible for preclinical research and development activities as laid out by the collaboration with Passage, which was first signed in 2018 and then amended in 2020. Under the updated agreement, Passage provides $5 million in funding each year for five years, and in exchange gets exclusive rights to resulting technologies and drug programs targeting rare diseases of the central nervous system that are caused by mutations in a single gene.

“We are pleased with the continued expansion of our R&D partnership with Passage Bio in our joint quest to develop transformative therapies for patients with devastating CNS disorders,” said Wilson, who also serves as Passage’s chief scientific advisor.

Investors, though, have been harder to please. As of Wednesday, Passage shares were down 65% compared to the $22 they traded at when the company went public in early 2020.

Passage’s share value rose about 1% to 2% following Wednesday’s announcement, to trade around $7.70.